EUCTR2008-008478-30-DE进行中（未招募）不适用
[Targetspezifische Second-line-Therapie des metastasierten Urothelkarzinoms mit Temsirolimus]Target-specific therapy of metastatic urothelial carcinoma with temsirolimus - Targetspezifische Second-line-Therapie des metastasierten Urothelkarzinoms mit Temsirolimus
ukaskrankenhaus GmbH0 个研究点开始时间: 2009年1月20日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •men and women,
- •at least 18 years
- •metastatic urothelial carcinoma
- •prvious chemotherapy with a cis-platin containing regimen
- •life expectancy
- •at least 6 months
- •karnofsky index at least 60%
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Impaired general health status, defined as Karnofsky-Index < 60%
- •Previous treatment with temsirolimus
- •Cardiac failure of NYHA stage 3 or 4
- •Psychiatric disorder
- •Pregnancy, lactation
- •Second malignant disease (exception: basalioma of skin) in previous 2 years
- •Participation in another therapeutical trial during 60 days preceding study start
- •Contraindications according to SmPC: Hypersensitivity to temsirolimus, its metabolites (including sirolimus), polysorbate 80, or to any of the excipients of temsirolimus
研究者
相似试验
进行中（未招募）
不适用
Dosisdichte 1st-line Therapie des metastasierten Mammakarzinoms mit Paclitaxel und liposomalem Doxorubicin (Myocet®)metastasiertes MammakarzinomMedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancerEUCTR2005-004234-41-DEOtto-von-Guericke Universität Magdeburg
进行中（未招募）
不适用
ocal cytoreductive treatments for men with newly diagnosed metastatic prostate cancer in addition to standard of care treatmentProstate cancerCancerISRCTN58401737Imperial College London and Imperial College Healthcare NHS Trust399
招募中
不适用
Combination of molecularly-targeted therapy with stereotactic body radiotherapy in hepatocellular carcinoma with major vascular invasioHepatocellular carcinoma with major vascular invasionJPRN-UMIN000030718Osaka International Cancer Institute20
尚未招募
不适用
Combination therapy of paclitaxel, ramucirumab, and TEW7197 as a secondary treatment for gastric cancerNeoplasmsKCT0005928Samsung Medical Center43
进行中（未招募）
1 期
Sequential first-line therapy in metastatic colorectal cancer with Capecitabine/FUFA, Irinotecan and Bevacizumabmetastatic colorectal cancerMedDRA version: 20.0 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 100000004864EUCTR2009-013099-38-DEKlinikum der Universität München, Anstalt des öffentlichen Rechts vertreten durch den Vorstand450